Modern management of chronic constipation
https://doi.org/10.21518/2079-701X-2013-1-2-98-100
Abstract
Chronic constipation (CC) is one of the most common disorders of bowel function occurring on average in 15% of population and in the majority of elderly and senile age people. Functional constipations (FC) are a challenge for diagnosis and treatment. Dyskinesia (irritable bowel syndrome with constipation predominance), hypokinesia (inert colon) and pelvic floor dyssynergia (defecation dyssynergia) are major factors of FL. The effectiveness of treatment depends on defining the etiology of constipation, instrumental evaluation of motor function of intestine and pelvic floor muscles. Rome III criteria 2006 help to make a well-based diagnosis of FL and irritable bowel syndrome with constipation (IBS-C). Motor regulators are prescribed for the treatment of the disorder. Patients with inert colon are recommended to take enterokinetics. These drugs accelerate colonic transit, improve stool consistency and reduce straining. Patients with bowel dyssynergic defecation should take biofeedback therapy (BFT).
Keywords
функциональный запор,
синдром раздраженного кишечника с запорами,
инертная толстая кишка,
диссинергическая дефекация,
регуляторы моторики толстой кишки,
энтерокинетики,
биофидбектерапия,
functional constipation,
irritable bowel syndrome with constipation,
inert colon,
dyssynergic defecation,
regulators of motility of the colon,
enterokinetics biofeedback therapy
About the Author
A. I. Parfyonov
the Central Scientific Research Institute for Gastroenterology, Moscow
Russian Federation
Russian Federation
References
1. Лазебник Л.Б., Прилепская С.И., Парфенов А.И. и др. Распространенность и факторы риска запоров у взрослого населения Москвы по данным популяционного исследования «МУЗА». Эксперим. и клин. гастроэнтерология 2011;3:68-73
2. Shah, N.D., Chitkara, D.K., Locke, G.R., et al. Ambulatory care for constipation in the United States, 1993–2004. Am J Gastroenterol 2008;103: 1746–1753
3. Choung, R.S., Branda, M.E., Chitkara, D., et al Longitudinal direct medical costs associated with constipation in women. Aliment Pharmacol The 201;33: 251–260
4. Wald, A., Scarpignato, C., Kamm, M.A. et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 2007;26: 227–236
5. Sun, S.X., Dibonaventura, M., Purayidathil, F.W. et al.Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci 2011;56: 2688–2695
6. Drossman D. A. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroen-terology 2006; 130 (5): 1377–9
7. Rao SSC. Dyssynergic Defecation. Gastroenterol Clin North Am. 2001;30:97–114
8. Рогозина В. А. Применение рентгеноконтрастных маркеров с целью изучения моторно-эвакуаторной функции толстой кишки. В сб.: Материалы IV Всесоюзного съезда. М.,Л. 1990;2:530–531
9. Rao, S.S., Kuo, B., McCallum, et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol 2009;7: 537–544
10. Camilleri, M., Thorne, N.K., Ringel, et al. Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil 2010; 22: 874–882
11. Парфенов А.И. Запоры. В кн.: Парфенов А.И. Энтерология: руководство для врачей. Изд 2-е. МИА. 2009;.201-213.
12. Camilleri, M., Kerstens, R., Rykx, A. and Vandeplassche, L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358: 2344–2354;
13. Quigley, E.M., Vandeplassche, L., Kerstens, R. and Ausma, J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29: 315–328
14. Tack, J., van Outryve, M., Beyens, G., Kerstens, R. and Vandeplassche, L. Prucalopride (Re-solor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58: 357–365
15. Manini, M.L., Camilleri, M., Goldberg, M., et al. Effects of Velusetrag (TD-5108) on gastroin-testinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010; 22: 42–49, e47–48
16. Bryant, A.P., Busby, R.W., Bartolini, W.P.,et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sciences2010; 86: 760–765
17. Lembo, A.J., Schneier, H.A., Shiff, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med2011; 365: 527–536
18. Barish CF, Drossman D, Johanson JF, et al. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010;55:1090–7
19. Becker G, Blum HE. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet 2009;373:1198–206
20. Buchler MW, Seiler CM, Monson JR, et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther 2008;28:312–25
21. Rao, A.S., Wong, B.S., Camilleri, M., et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010; 139: 1549–1558, 1558 e1541
22. Simren, M., Bajor, A., Gillberg, P.G.,et al. Randomised clinical trial: The ileal bile acid trans-porter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study. Aliment Pharmacol Ther2011; 34: 41–50
23. Парфенов А.И., Ручкина И.Н. Профилактика и лечение запоров пробиотиками. Фармате-ка, 2006; 12 (127): 23-29
24. Siddharth Singh, Satish S.C. Rao. Pharmacologic Management of Chronic Constipation. Gas-troenterol.Clin.N.Am. 2010;39:509-527
25. Rao S.K. et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol 2007;5:335
26. Joo JS, Agachan F, Wolff B, et al. Initial North American Experience with Botulinum Toxin Type A for Treatment of Anismus. Dis Colon Rectum 1996;39:1107–11
27. Kаmm М.А. Clinical Case: Chronic Constipation Gastroenterology 2006;131:23В 3–239
Review
For citations:
Parfyonov AI. Modern management of chronic constipation. Meditsinskiy sovet = Medical Council. 2013;(1-2):98-100. (In Russ.) https://doi.org/10.21518/2079-701X-2013-1-2-98-100
Views:
2706
Email this article 